<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040634</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL-DIABETES Trial</org_study_id>
    <secondary_id>02795218.8.1001.0071</secondary_id>
    <secondary_id>25000.028978/2018-02</secondary_id>
    <nct_id>NCT04040634</nct_id>
  </id_info>
  <brief_title>Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)</brief_title>
  <official_title>Large-Scale Randomized Clinical Trial Assessing Intensive Blood Pressure Control for Reduction of Major Cardiovascular Events in Patients With Diabetes Mellitus (OPTIMAL-DIABETES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure (BP) is a major public health concern, especially in low and middle&#xD;
      income countries. High BP is a highly prevalent condition, and it is usually associated with&#xD;
      diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events&#xD;
      including cardiovascular death, acute myocardial infarction, stroke, unstable angina and&#xD;
      heart failure. In addition, high BP is also related to cognitive decline. The&#xD;
      OPTIMAL-DIABETES trial consists of a two-arm, multicenter, randomized clinical trial designed&#xD;
      to test whether a lower systolic blood pressure (SBP) target will reduce the occurrence of&#xD;
      major cardiovascular events in diabetic patients compared to the standard SBP target.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to total death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to first event of total death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cardiovascular Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from renal causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Myocardial Infarction (MI)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ischemic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hemorrhagic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Undetermined type of Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Undetermined type of Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Transient Ischemic Attack (TIA)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to transient ischemic attack (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization for Unstable Angina</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Hospitalization for unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization for Heart Failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Outcome</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Renal Outcome, defined as a 50% reduction in the glomerular filtration rate (GRF) associated with a final GFR of &lt; 60 mL/min/1.73m2 in patients without chronic kidney disease (GFR 60-90 mL/min/1.73m2) at baseline. In those patients with chronic kidney disease (&lt;60 mL/min/1.73m2) at baseline, the renal outcome will be defined as a 50% reduction in GFR or progression of renal disease to stage IV, requiring dialysis or kidney transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mild Cognitive Impairment</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Mild Cognitive Impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mild Cognitive Impairment or All-Cause Probable Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to mild cognitive impairment or all-cause probable dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Probable Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all-cause probable dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Brain Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Total Brain Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Matter Lesions Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>White Matter Lesions Volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9479</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>High Blood Pressure</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP &lt;120 mm Hg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized into the Standard arm will have a goal of SBP &lt;140 mm Hg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>Participants in the Intensive arm have a goal of SBP &lt;120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged.</description>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <other_name>Intensive BP control targeting SBP &lt;120 mm Hg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>The same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
    <arm_group_label>Standard Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <other_name>Standard control of SBP targeting SBP &lt; 140 mm Hg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systolic Blood Pressure (SBP) between 130 and 180 mm Hg:&#xD;
&#xD;
               -  130 to 150 mm Hg (if on 0-4 medications)&#xD;
&#xD;
               -  130 to 160 mm Hg (if on 0-3 medications)&#xD;
&#xD;
               -  130 to 170 mm Hg (if on 0-2 medications)&#xD;
&#xD;
               -  130 to 180 mm Hg (if on 0-1 medications)&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  To be considered as having a high cardiovascular risk, including AT LEAST ONE of the&#xD;
             following factors:&#xD;
&#xD;
               1. Established cardiovascular disease (CVD), including:&#xD;
&#xD;
                    -  Coronary artery disease: previous myocardial infarction, previous acute&#xD;
                       coronary syndrome, previous percutaneous coronary intervention, previous&#xD;
                       coronary artery bypass graft surgery, or at least 50% stenosis in a main&#xD;
                       coronary artery associated with typical angina pectoris; or&#xD;
&#xD;
                    -  Cerebrovascular disease: previous stroke (except those events caused by&#xD;
                       intracranial aneurysm or arteriovenous malformation) or previous transient&#xD;
                       ischemic attack (TIA), stable for at least 2 weeks preceding inclusion in&#xD;
                       the study; or&#xD;
&#xD;
                    -  Carotid artery disease: previous carotid endarterectomy, previous&#xD;
                       percutaneous intervention with carotid stent implantation, or stenosis of at&#xD;
                       least 50% in a carotid shown by the Doppler ultrasonography, CT angiography&#xD;
                       or MR angiography; or&#xD;
&#xD;
                    -  Peripheral artery disease: prior surgical or percutaneous revascularization&#xD;
                       of a peripheral artery, limb amputation due to vascular cause, abdominal&#xD;
                       aortic aneurysm ≥ 5 cm (with or without prior surgical or percutaneous&#xD;
                       repair), or stenosis of at least 50% in a peripheral artery associated to&#xD;
                       intermittent claudication.&#xD;
&#xD;
               2. Subclinical CVD, including:&#xD;
&#xD;
                    -  Coronary calcium score ≥ 300 Agatston units; or&#xD;
&#xD;
                    -  Ankle-brachial index ≤ 0.90 in the last two years; or&#xD;
&#xD;
                    -  Left ventricular hypertrophy on the electrocardiogram, echocardiogram or&#xD;
                       other cardiac imaging exam in the last two years.&#xD;
&#xD;
               3. Chronic kidney disease (CKD):&#xD;
&#xD;
                  ▪ Definition of CKD: glomerular filtration rate (GFR) between 20 and 59&#xD;
                  ml/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration&#xD;
                  (CKD-EPI).&#xD;
&#xD;
               4. Additional cardiovascular risk factors, including:&#xD;
&#xD;
                    -  Active smoking: Defined as regular use of cigarettes or other tobacco&#xD;
                       products, such as cigars and pipe, in the last six months;&#xD;
&#xD;
                    -  Dyslipidemia: Defined as LDL cholesterol &gt; 70 mg/dL or non-HDL cholesterol &gt;&#xD;
                       100 mg/dL in patients with previous CVD; or LDL cholesterol &gt; 100 mg/dL or&#xD;
                       non-HDL cholesterol &gt; 130 mg/dL in patients without previous CVD; or&#xD;
                       Triglycerides &gt; 200 mg/dL or HDL &lt; 40 mg/dL regardless of treatment; or use&#xD;
                       of statins or other lipid lowering medication; or&#xD;
&#xD;
                    -  Age ≥ 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to provide written informed consent&#xD;
&#xD;
          -  Body mass index &gt; 45 kg/m2&#xD;
&#xD;
          -  Known secondary cause of hypertension&#xD;
&#xD;
          -  Severe renal dysfunction with GFR &lt; 20 mL/min/1.73m2 calculated by the CKD-EPI&#xD;
             equation&#xD;
&#xD;
          -  Angina at rest Class IV Canadian Cardiovascular Society (CCS)&#xD;
&#xD;
          -  Acute coronary syndrome in the last six months&#xD;
&#xD;
          -  Symptomatic heart failure Class IV New York Heart Association (NYHA) or ejection&#xD;
             fraction &lt; 35% on Doppler echocardiography in the last six months&#xD;
&#xD;
          -  Factors that at the research team´s judgment may limit adherence to the intervention&#xD;
             and study protocol, including, but not limited to, the following examples:&#xD;
&#xD;
               -  Recent history of alcohol and illicit drug abuse&#xD;
&#xD;
               -  Psychiatric comorbidities (severe depression, schizophrenia, psychosis, etc.)&#xD;
&#xD;
               -  History of poor medication adherence and attendance to consultations&#xD;
&#xD;
               -  Any plans to move the city of residence in the next four years&#xD;
&#xD;
               -  Any plans to leave the city of residence for more than three months in the next&#xD;
                  few years&#xD;
&#xD;
               -  Living in the same residence of another patient previously included in this study&#xD;
&#xD;
          -  Patients currently enrolled in another study for CVD prevention, including those&#xD;
             evaluating pharmacological and non-pharmacological interventions&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas Dr Marco Mota</name>
      <address>
        <city>Maceió</city>
        <state>Alagoas</state>
        <zip>57051-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas em Diabetes e Doenças Endocrino-Metabólicas</name>
      <address>
        <city>Fortaleza</city>
        <state>Bahia</state>
        <zip>60430-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40323-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Estudos E Pesquisas Clinicas Do Ceara</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Hospital de Base</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70330-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Cassiano Antonio de Moraes</name>
      <address>
        <city>Vitória</city>
        <state>Espirito Santo</state>
        <zip>29043-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NS Clínica de Diabetes e Endocrinologia Ltda</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Universidade Federal de Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Hospital Santa Lúcia</name>
      <address>
        <city>Poços De Caldas</city>
        <state>Minas Gerais</state>
        <zip>37710-005</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Nuclear Alto da XV</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário João de Barros Barreto - UFPA</name>
      <address>
        <city>Belém</city>
        <state>Pará</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro Cardiológico de Pernambuco Prof. Luiz Tavares da Silva</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50100-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <zip>49055-530</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Endocrinologia Geloneze</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indacor Servicos Medicos Ltda</name>
      <address>
        <city>Indaiatuba</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integrado de Pesquisas</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Vilela &amp; Martin</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-365</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia e Endocrinologia Rio Preto Ltda</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15091-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Cardiológica</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <zip>15505-189</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Ciências Médicas - Universidade do Estado do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Metabologia e Hipertensão da Universidade Federal de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04025-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Da Santa Casa de Misericordia de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Real e Benemérita Associação Portuguesa de Beneficência/SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

